Healthcare company-building profile
Mount Sinai Innovation Partners
Mount Sinai Health System / Icahn School of Medicine at Mount Sinai
Source-based profile
Program at a Glance
- Program type
- Accelerator
- Program category
- Health system accelerator
- Organization
- Mount Sinai Health System / Icahn School of Medicine at Mount Sinai
- Organization type
- Hospital or health system
- Location
- New York, New York
- Company stage served
- Research or idea stage
- Cohort or participation model
- Not publicly documented
- Investment or funding offered
- Not publicly documented
- Published investment terms
- Not publicly documented
- Equity or fee model
- Not publicly documented
- Clinical or hospital connection
- Yes
- Application status
- Active
- Founded
- 2018 (i3 Asset Accelerator)
Public description
About the program
Mount Sinai Innovation Partners (MSIP) is the commercialization organization for the Mount Sinai Health System and the Icahn School of Medicine, handling patenting, licensing, research partnerships and entrepreneurship. In 2018 the Icahn School of Medicine capitalized the i3 Asset Accelerator with an initial $10 million to fast-track commercially relevant discoveries toward patients using a milestone-based development strategy. The accelerator is guided by an advisory team of more than 40 scientists, business professionals and commercialization experts who both allocate funding and steer development. Early funded assets included a novel drug-development platform for cancer and therapies for influenza B. The combination gives Mount Sinai an internal capital vehicle for its own science rather than an external venture fund.
What the program publicly emphasizes
Focus areas and features
- Category: Health system accelerator
Publicly documented people and network
Program leadership and alumni
- Program leader
- Erik Lium, PhD — President, Mount Sinai Innovation Partners; Chief Commercial Innovation Officer, Mount Sinai Health System
- Notable alumni named in public materials
- Erik Lium promoted to Executive Vice President of MSIP in 2018 after building the office's commercialization portfolio; MSIP maintains a venture/portfolio investment arm tracked by CB Insights; dedicated managing directors for business development, technology transactions/IP and strategic alliances; i3 Asset Accelerator launched in 2018 with an initial $10 million commitment; advisory team of more than 40 scientists and commercialization experts; first funded projects were a novel cancer drug-development platform led by Ross Cagan, PhD and Arvin Dar, PhD, and influenza B therapies led by Florian Krammer, PhD
Sources
External source links open in a new tab.